Physician profile
Blake W Moore
NPI 1992903769
$42,047.19
in general payments reported to CMS, 2019-2025
45 companies · $34K in 2025
The $34K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,071 · 2020: $269 · 2021: $742 · 2022: $740 · 2023: $1,049 · 2024: $617 · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $2,410 · Travel and Lodging: $556 · Education: $8.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,250.00 |
| Food and Beverage | $2,409.57 |
| Travel and Lodging | $556.37 |
| Education | $8.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $32,250.00 | 2025 | Motoband Cp, Motoband |
| Intuitive Surgical, INC. | $4,327.24 | 2019 | |
| Conmed Corporation | $635.95 | 2019-2025 | Airseal |
| Janssen Biotech, INC. | $621.06 | 2019-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $578.31 | 2022-2025 | |
| Abbvie INC. | $379.56 | 2020-2025 | |
| Blue Earth Diagnostics | $361.70 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $306.14 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $289.69 | 2019-2024 | Provenge |
| Urogen Pharma, INC. | $228.86 | 2021-2025 | Jelmyto |
| Merck Sharp & Dohme LLC | $199.45 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $176.20 | 2019-2023 | Xtandi |
| Pfizer INC. | $174.88 | 2022-2025 | |
| Endo Pharmaceuticals INC. | $133.71 | 2019-2022 | |
| Myovant Sciences INC. | $129.63 | 2021-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.